RhyGaze, a biotechnology company with headquarters in Basel, Switzerland, and Philadelphia, PA, has ...

InflammX Therapeutics, Inc. has announced an option agreement with Bausch + Lomb, granting the latte...

Ocugen has announced that the first patient in its Phase 1 clinical trial for OCU200, a potential tr...

Outlook Therapeutics has finalized the analysis of 12-week safety and efficacy data from the NORSE E...

Prevent Blindness, a leading organization dedicated to promoting eye health, announced it has receiv...

Inflammasome Therapeutics has announced encouraging 3-month topline results from a clinical trial ev...

4D Molecular Therapeutics (4DMT) has released promising topline interim data from Part 1 of the SPEC...

Ocugen, Inc. has announced encouraging 2-year safety and efficacy results from its Phase 1/2 clinica...

AbbVie and Regenxbio have announced updates on the clinical development of ABBV-RGX-314, a potential...

PulseSight Therapeutics SAS has submitted a clinical trial authorization (CTA) to the Agence Nationa...